Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Eiken Chemical Co., Ltd. ( (JP:4549) ) is now available.
Eiken Chemical reported consolidated net sales of ¥31.38 billion for the nine months ended December 31, 2025, up 2.4% year on year, with operating profit rising 5.5% to ¥2.78 billion and profit attributable to owners of parent jumping 75.8% to ¥3.72 billion, supported in part by a lower share count that also lifted basic earnings per share to ¥112.94. The company’s equity ratio improved to 72.5% and net assets per share increased, while it maintained its full-year forecast for FY2025 (ending March 31, 2026), targeting 4.1% sales growth and a 69.2% rise in full-year profit attributable to owners of parent, and plans to raise the annual dividend to ¥58 per share, signaling confidence in earnings resilience and a continued commitment to shareholder returns despite a projected decline in ordinary profit.
The most recent analyst rating on (JP:4549) stock is a Hold with a Yen2306.00 price target. To see the full list of analyst forecasts on Eiken Chemical Co., Ltd. stock, see the JP:4549 Stock Forecast page.
More about Eiken Chemical Co., Ltd.
Eiken Chemical Co., Ltd. is a Japan-based medical diagnostics manufacturer listed on the Tokyo Stock Exchange, specializing in clinical testing reagents and related diagnostic equipment for hospitals and laboratories. The company focuses on supplying diagnostic solutions in domestic and overseas markets, positioning itself as a key player in the healthcare testing and in-vitro diagnostics sectors.
Average Trading Volume: 85,722
Technical Sentiment Signal: Buy
Current Market Cap: Yen79.68B
For a thorough assessment of 4549 stock, go to TipRanks’ Stock Analysis page.